Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Bread Financial Holdings, Inc. Common Stock
Torchmark Corp
Zura Bio Limited - Class A Ordinary shares
Edit Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Syndax Pharmaceuticals, Inc.
< Previous
1
2
Next >
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
November 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
November 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
November 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
November 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
October 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Participation in November Investor Conferences
October 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
October 26, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
October 15, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
October 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Participation in September Investor Conferences
September 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
August 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
July 28, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
July 14, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 04, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 02, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 01, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
May 12, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
April 24, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SNDX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.